Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 111 for:    nrp 104 OR lisdexamfetamine

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02635035
Recruitment Status : Completed
First Posted : December 18, 2015
Last Update Posted : September 24, 2019
Sponsor:
Collaborator:
Shire
Information provided by (Responsible Party):
NYU Langone Health

Tracking Information
First Submitted Date  ICMJE November 18, 2015
First Posted Date  ICMJE December 18, 2015
Last Update Posted Date September 24, 2019
Study Start Date  ICMJE November 2015
Actual Primary Completion Date January 9, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 15, 2015)
Changes in the number of symptoms present from the BAARS-IV; Barkley SCT Scale in adults with SCT or SCT and ADHD treated with lisdexamfetamine dimesylate (LDX) versus placebo. [ Time Frame: 10 Weeks ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02635035 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: December 15, 2015)
  • Changes in measure of arousal and motivation measured by BRIEF-A Metacognition Index and Motivation Subscales [ Time Frame: 10 Weeks ]
  • Changes in score on neuropsychological tests of arousal and alerting, including: the Cambridge Neuropsychological Testing Automated Battery (CANTAB) ADHD battery [ Time Frame: 10 Weeks ]
  • Changes in measures of reaction time and reaction time variability as measured by the Attention Switching Task (AST) [ Time Frame: 10 Weeks ]
  • Changes in the measure of processing time measured by Wechsler Adult Intelligence Scale-IV [ Time Frame: 10 Weeks ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
Official Title  ICMJE Efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT)
Brief Summary The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a placebo controlled, cross-over clinical trial of oral Lisdexamfetamine Dimesylate 30-70mg/day in adults with attention-deficit hyper-activity disorder and Sluggish Cognitive Tempo (ACT). Patients will be assigned either LDX/Placebo for 10 weeks with a two week placebo washout period.
Detailed Description

Sluggish Cognitive Tempo (SCT) describes individuals who are dreamy, spacey, slow moving, hyper active, have difficulty initiating tasks, and often seem under-motivated and under-aroused. Barkley identified nine cardinal symptoms of SCT: 1) prone to daydreaming instead of concentrating; 2) trouble staying alert/awake in boring situations; 3) being easily confused; 4) being easily bored; 5) feeling spacey/in a fog; 6) frequently feeling lethargic; 7) being under-active/having less energy than others; 8) being slow moving; 9) not processing information quickly/accurately. Individuals were identified as SCT if they had at least 5 of 9 symptoms rated often or very often on the 9-item SCT subscale from the Barkley Adult ADHD Rating Scale-IV: Self-Report (BAARS-IV; hereafter called the Barkley SCT Scale).

This is a 2 Site (NYU and Mount Sinai) Study of LDX in 50 adults with Attention Deficit Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). The study will be a double-blind, 10-week, cross-over treatment trial of LDX (4 weeks; 30 - 70 mg/day) vs. placebo (4 weeks) with an intervening single- blind placebo washout period (2 weeks). During the LDX treatment period, LDX treatment will be initiated at a dose of 30mg/day at Visit 0 and can be titrated up (in the judgment of the investigator) in increments of 20mg, based upon clinical response and tolerability, to 50mg/day at Visit 1 and 70mg/day at Visit 2. Subjects receiving daily doses of 50mg or 70mg of LDX will be allowed to down titrate one dosage step of 20mg during Visits 2-4 if (in the judgment of the investigator) they are having issues in tolerability. The highest effective dose of LDX will then be maintained until Visit 4. Patients will be seen weekly throughout the trial except during placebo washout.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Attention Deficit Disorder
  • Attention Deficit Hyperactivity Disorder
Intervention  ICMJE
  • Drug: Lisdexamfetamine
    Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
    Other Name: Vyvanse
  • Drug: Placebo
    Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
Study Arms  ICMJE
  • Experimental: Lisdexamfetamine First
    In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
    Interventions:
    • Drug: Lisdexamfetamine
    • Drug: Placebo
  • Experimental: Lisdexamfetamine Second
    In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
    Interventions:
    • Drug: Lisdexamfetamine
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 23, 2019)
86
Original Estimated Enrollment  ICMJE
 (submitted: December 15, 2015)
120
Actual Study Completion Date  ICMJE January 9, 2019
Actual Primary Completion Date January 9, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female between the ages of 18-60 of all races and ethnicity.
  2. Meets DSM-IV-TR criteria for a primary diagnosis of inattentive or combined type ADHD as diagnosed via the Adult ADHD Clinician Diagnostic Scale
  3. For the Sluggish Cognitive Tempo+ group Must Score ≥ 5 items on the Barkley Sluggish Cognitive Tempo Scale; Must be rated 3 ("often") or ("very often") and total Sluggish Cognitive Tempo symptom score ≥ 26; must have a T-score ≥ 65 on the Metacognition Index and Motivation Subscales of the Behavior RatingInventory of Executive Function - Adult Version (BRIEF-A)
  4. Impairment: must have a total score > 95th percentile on the Barkley Functional Impairment Rating Screen (Barkley Functional Impairment Scale (BFIS).
  5. For the Sluggish Cognitive Tempo - group, < 5 items on the Barkley SCT Scale must be rated 3 ("often") or 4 ("very often") and total SCT symptom score < 26; must have a T-score < 65 on the Metacognition Index and Motivation Subscales of the BRIEF-A.

Exclusion Criteria:

  1. Meets DSM-IV-TR criteria for a primary diagnosis of hyperactive-impulsive type ADHD.
  2. Any other current psychiatric disorder, determined via the M.I.N.I , which requires pharmacotherapy treatment.
  3. Current suicidal ideation or history of suicide attempts, based on the Columbia- Suicide Severity Rating Scale(C-SSRS).
  4. Lifetime history of bipolar disorder or any psychotic disorder as per the M.I.N.I
  5. Pregnant, breastfeeding or women planning to become pregnant.
  6. Positive urine drug toxicology are excluded.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02635035
Other Study ID Numbers  ICMJE 13-01288
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party NYU Langone Health
Study Sponsor  ICMJE NYU Langone Health
Collaborators  ICMJE Shire
Investigators  ICMJE
Principal Investigator: Lenard Adler, M.D. NYU Medical College
PRS Account NYU Langone Health
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP